BioNTech SE (F:22UA) — Market Cap & Net Worth
Market Cap & Net Worth: BioNTech SE (22UA)
BioNTech SE (F:22UA) has a market capitalization of $20.05 Billion (€17.15 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #1290 globally and #287 in its home market, demonstrating a -2.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioNTech SE's stock price €86.55 by its total outstanding shares 252884261 (252.88 Million). Also see BioNTech SE (22UA) total assets for a full breakdown of the balance sheet.
BioNTech SE Market Cap History: 2019 to 2026
BioNTech SE's market capitalization history from 2019 to 2026. Data shows growth from $9.02 Billion to $25.59 Billion (31.46% CAGR). Also see 22UA cash flow metrics for how efficiently the company converts equity into cash flow.
BioNTech SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioNTech SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BioNTech SE share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.42x
BioNTech SE's market cap is 8.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $9.02 Billion | $108.59 Million | -$179.06 Million | 83.04x | N/A |
| 2020 | $21.46 Billion | $482.32 Million | $15.20 Million | 44.50x | 1412.30x |
| 2021 | $63.27 Billion | $18.98 Billion | $10.29 Billion | 3.33x | 6.15x |
| 2022 | $42.59 Billion | $17.31 Billion | $9.43 Billion | 2.46x | 4.51x |
| 2023 | $28.09 Billion | $3.82 Billion | $930.30 Million | 7.35x | 30.19x |
| 2024 | $32.14 Billion | $2.75 Billion | -$665.30 Million | 11.68x | N/A |
| 2025 | $24.17 Billion | $2.87 Billion | -$1.14 Billion | 8.42x | N/A |
Competitor Companies of 22UA by Market Capitalization
Companies near BioNTech SE in the global market cap rankings as of September 16, 2026. Review BioNTech SE tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BioNTech SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
BioNTech SE Historical Marketcap From 2019 to 2026
Between 2019 and today, BioNTech SE's market cap moved from $9.02 Billion to $ 25.59 Billion, with a yearly change of 31.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €25.59 Billion | +5.87% |
| 2025 | €24.17 Billion | -24.79% |
| 2024 | €32.14 Billion | +14.42% |
| 2023 | €28.09 Billion | -34.05% |
| 2022 | €42.59 Billion | -32.69% |
| 2021 | €63.27 Billion | +194.77% |
| 2020 | €21.46 Billion | +138.03% |
| 2019 | €9.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of BioNTech SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.05 Billion USD |
| MoneyControl | $20.05 Billion USD |
| MarketWatch | $20.05 Billion USD |
| marketcap.company | $20.05 Billion USD |
| Reuters | $20.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more